ArticleBMC cancer2024
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2026Pooled it
- De-escalation of breast surgery for early stage breast cancer.Japanese journal of clinical oncology · 2026Review
- Dynamic Assessment of Systemic Inflammatory Markers in Predicting Pathological Complete Response After Neoadjuvant Treatment in Triple-Negative Breast Cancer.Journal of clinical medicine · 2026Article
- Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.Future oncology (London, England) · 2026Observational
- Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review).Oncology letters · 2026Review
- Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting.Discover oncology · 2026Review
- Current perspectives on circulating tumor DNA in breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Circulating tumor DNA in neoadjuvant therapy for solid tumors.Frontiers in oncology · 2026Review
- Article
- Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.Future science OA · 2025Review
- Liquid biopsies across the cancer care continuum.Nature medicine · 2025Review
- Unraveling the Potential of ctDNA in Precision Medicine for Breast Cancer.Molecular diagnosis & therapy · 2025Review
- Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical Utility.Cancers · 2025Review
- Liquid biopsy in advanced and metastatic breast cancer: translating prognostic value to clinical implementation.Translational cancer research · 2025Article
- Minimal residue disease detection in early-stage breast cancer: a review.Molecular biology reports · 2025Review
- Clinical Management of Circulating Tumor DNA in Breast Cancer: Detection, Prediction, and Monitoring.Breast cancer (Dove Medical Press) · 2025Review
- Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring.Frontiers in oncology · 2025Review
- The role of circulating tumor DNA in gynecological cancer management.Frontiers in oncology · 2025Review
- Prognostic utility of inflammatory indices and circulating nucleic acids for neoadjuvant chemotherapy outcomes in breast cancer: a systematic review.Therapeutic advances in medical oncology · 2025Review
- Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA.BMC women's health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundTriple negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. We aimed to determine whether circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) could predict response and long-term outcomes to neoadjuvant chemotherapy (NAC).
methodsPatients with TNBC were enrolled between 2017-2021 at The University of Texas MD Anderson Cancer Center (Houston, TX). Serial plasma samples were collected at four timepoints: pre-NAC (baseline), 12-weeks after NAC (mid-NAC), after NAC/prior to surgery (post-NAC), and one-year after surgery. ctDNA was quantified using a tumor-informed ctDNA assay (Signatera
resultsIn total, 37 patients were enrolled. The mean age was 50 and majority of patients had invasive ductal carcinoma (34, 91.9%) with clinical T2, (25, 67.6%) node-negative disease (21, 56.8%). Baseline ctDNA was detected in 90% (27/30) of patients, of whom 70.4% (19/27) achieved ctDNA clearance by mid-NAC. ctDNA clearance at mid-NAC was significantly associated with pathologic complete response (p = 0.02), whereas CTC clearance was not (p = 0.52). There were no differences in overall survival (OS) and recurrence-free survival (RFS) with positive baseline ctDNA and CTC. However, positive ctDNA at mid-NAC was significantly associated with worse OS and RFS (p = 0.0002 and p = 0.0034, respectively).
conclusionsEarly clearance of ctDNA served as a predictive and prognostic marker in TNBC. Personalized ctDNA monitoring during NAC may help predict response and guide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.